「台糖衛舒寧」乳酸菌產品具有減少人體幽門螺桿菌之功能

本試驗係以台灣糖業股份有限公司生物科技事業部提供之「台糖衛舒寧」乳酸菌產品（以下稱試驗物質）（台美檢體編號：M62-160600018），依照行政院衛生福利部公告之「健康食品之胃腸道功能改善評估方法」進行減少人體幽門螺桿菌功能試驗。本實驗招募40名經篩檢有中或高菌量之幽門螺桿菌感染者參加試驗，隨機分派為試驗組及對照組，每組人數為20人，試驗為期4週，每日服用試驗物質或對照物質（不含乳酸菌擬似品）。於第4週時，比較試驗組與對照組之∆UBT值，結果指出試驗組具有顯著下降之情形（p ＜ 0.05）；且試驗組之∆UBT值在試驗後，亦比試驗前具有顯著下降之情形（p ＜ 0.05）。此外，結果亦顯示在試驗前、後受試者之各項血清生化值在統計上並無顯著差異（p ＞ 0.05）。綜合上述結果，間接地指出「台糖衛舒寧」，在本試驗設計條件下，具有減少幽門螺桿菌菌量之功能。

關鍵字

台糖衛舒寧；幽門螺桿菌；胃腸道功能

並列摘要

The ＂TAISUGAR WEISHUNING＂ is a Lactobacillus product of the Taiwan Sugar Corporation. In this study, the effect of this product on Helicobacter pylori load in humans was investigated. The study was conducted in accordance with the ＂Methods for Evaluating the Improvement in Gastrointestinal Function by Healthy Foods＂ published by the Ministry of Health and Welfare of Taiwan. Forty individuals with moderate to high H. pylori loads were recruited and randomly assigned to experimental and control groups with 20 subjects in each group. The experimental subjects consumed TAISUGAR WEISHUNING, and the control subjects consumed lactic acid bacteria (LAB)-free placebo daily during the 4- week trial period. Results showed that the ∆UBT (difference in the values of urea breath test) values of subjects in the experimental group were significantly lower than those of subjects in the control group (p ＜ 0.05), indicating a reduction in H. pylori load after taking TAISUGAR WEISHUNING for 4 weeks. In addition, the post-trial ∆UBT values of the experimental group were significantly lower than those of the pre-trial values (p ＜ 0.05). There was no significant difference between pre-trial and post-trial serum biochemical values of the subjects (p ＞ 0.05). Taken together, results of this study suggest the TAISUGAR WEISHUNING is capable of reducing H. pylori load in humans.

並列關鍵字

TAISUGAR WEISHUNING ； Helicobacter pylori ； gastrointestinal function

國際替代計量

「台糖衛舒寧」乳酸菌產品具有減少人體幽門螺桿菌之功能

全文下載

主題瀏覽